TREATMENT OPTIONS IN ONCOLOGY:@0.084848:0.038601:0.493541:0.038601:0.493541:0.019343:0.084848:0.019343:0.010019:0.014276:0.012606:0.015487:0.010019:0.021613:0.012606:0.017404:0.010019:0.006515:0.020438:0.013923:0.010019:0.005315:0.020438:0.017404:0.011712:0.006515:0.005315:0.017404:0.006515:0.020438:0.017404:0.019121:0.020438:0.010866:0.020438:0.020508:0.013923
26:@0.023705:0.038809:0.044778:0.038809:0.044778:0.019212:0.023705:0.019212:0.010536:0.010536
HANDBOOK OF ONCOLOGY:@0.084848:0.970015:0.320957:0.970015:0.320957:0.956010:0.084848:0.956010:0.011682:0.012657:0.012657:0.012726:0.009818:0.014864:0.014864:0.010109:0.004738:0.014864:0.008296:0.004738:0.014864:0.012657:0.013906:0.014864:0.007902:0.014864:0.014915:0.010126
Other  tumours overexpressing SSTs, such :@0.084848:0.096166:0.481107:0.096166:0.481107:0.080410:0.084848:0.080410:0.016722:0.006523:0.011738:0.012508:0.005792:0.005330:0.005338:0.006523:0.011699:0.018049:0.012604:0.011699:0.005792:0.007466:0.010680:0.012604:0.010660:0.012508:0.005711:0.012508:0.009236:0.013123:0.005713:0.012508:0.007466:0.007466:0.003848:0.011738:0.012950:0.010680:0.009583:0.009583:0.007753:0.007466:0.005330:0.010680:0.007466:0.011699:0.012450:0.011738:0.005330
as paraganglioma/pheochromocytoma, :@0.084848:0.112636:0.481094:0.112636:0.481094:0.096880:0.084848:0.096880:0.013143:0.007466:0.012892:0.013123:0.013143:0.005792:0.013143:0.012950:0.013143:0.011738:0.012950:0.003848:0.003848:0.012604:0.018049:0.013143:0.008409:0.013123:0.011738:0.012508:0.012604:0.012450:0.011738:0.005702:0.012604:0.018049:0.012604:0.012450:0.010314:0.006523:0.012604:0.018049:0.013143:0.005330:0.005330
neuroblastoma, and medullary thyroid :@0.084848:0.129106:0.481094:0.129106:0.481094:0.113350:0.084848:0.113350:0.011738:0.012508:0.011699:0.005707:0.012604:0.013123:0.003848:0.013143:0.007466:0.006523:0.012604:0.018049:0.013143:0.005330:0.016356:0.013143:0.011738:0.013181:0.016356:0.018049:0.012508:0.013181:0.011699:0.003848:0.003848:0.013143:0.005792:0.010314:0.016356:0.006523:0.011738:0.010314:0.005709:0.012604:0.003848:0.013181:0.005330
carcinoma may be treated as well. The :@0.084848:0.145577:0.481063:0.145577:0.481063:0.129821:0.084848:0.129821:0.012450:0.013143:0.005657:0.012450:0.003848:0.011738:0.012604:0.018049:0.013143:0.009333:0.018049:0.013143:0.010314:0.009333:0.013123:0.012508:0.009333:0.006523:0.005709:0.012508:0.013143:0.006523:0.012508:0.013181:0.009333:0.013143:0.007466:0.009333:0.015990:0.012508:0.003848:0.003848:0.005330:0.009333:0.008197:0.011738:0.012508:0.005330
ideal patients are those with well differen-:@0.084848:0.162047:0.475754:0.162047:0.475754:0.146291:0.084848:0.146291:0.003848:0.013181:0.012508:0.013143:0.003848:0.005830:0.013123:0.013143:0.006523:0.003848:0.012508:0.011738:0.006523:0.007466:0.005830:0.013143:0.005713:0.012508:0.005830:0.006523:0.011738:0.012604:0.007466:0.012508:0.005830:0.015990:0.003848:0.006523:0.011738:0.005830:0.015990:0.012508:0.003848:0.003848:0.005830:0.013181:0.003848:0.006102:0.006042:0.012508:0.005711:0.012508:0.011738:0.006388
tiated tumours, Ki67 ≤20%.:@0.084848:0.178517:0.324397:0.178517:0.324397:0.162761:0.084848:0.162761:0.006523:0.003848:0.013143:0.006523:0.012508:0.013181:0.005330:0.006523:0.011699:0.018049:0.012604:0.011699:0.005792:0.007466:0.005330:0.005330:0.011372:0.003848:0.010660:0.010660:0.005330:0.010564:0.010660:0.010660:0.014913:0.005330
Contra-indications  to  PRRNT  include  the :@0.084848:0.211458:0.481094:0.211458:0.481094:0.195702:0.084848:0.195702:0.015644:0.012604:0.011738:0.006523:0.005792:0.013143:0.006388:0.003848:0.011738:0.013181:0.003848:0.012450:0.013143:0.006523:0.003848:0.012604:0.011738:0.007466:0.005330:0.005255:0.006523:0.012604:0.005330:0.005255:0.011392:0.011680:0.011680:0.014239:0.008197:0.005330:0.005245:0.003848:0.011738:0.012450:0.003848:0.011699:0.013181:0.012508:0.005330:0.005263:0.006523:0.011738:0.012508:0.005330
following::@0.084848:0.227928:0.173652:0.227928:0.173652:0.212172:0.084848:0.212172:0.006042:0.012604:0.003848:0.003848:0.012604:0.015990:0.003848:0.011738:0.012950:0.005330
n   :@0.084848:0.241296:0.107657:0.241296:0.107657:0.232855:0.084848:0.232855:0.009762:0.003566:0.005914:0.003566
Pregnancy:@0.104091:0.244415:0.206031:0.244415:0.206031:0.228659:0.104091:0.228659:0.011392:0.005709:0.012508:0.012950:0.011738:0.013143:0.011738:0.012450:0.010314
n   :@0.084848:0.257768:0.107657:0.257768:0.107657:0.249327:0.084848:0.249327:0.009762:0.003566:0.005914:0.003566
Severe acute concomitant illnesses:@0.104091:0.260887:0.432249:0.260887:0.432249:0.245131:0.104091:0.245131:0.009583:0.012508:0.010660:0.012508:0.005713:0.012508:0.005330:0.013143:0.012450:0.011699:0.006523:0.012508:0.005330:0.012450:0.012604:0.011738:0.012450:0.012604:0.018049:0.003848:0.006523:0.013143:0.011738:0.006523:0.005330:0.003848:0.003848:0.003848:0.011738:0.012508:0.007466:0.007466:0.012508:0.007466
n   :@0.084848:0.274240:0.107657:0.274240:0.107657:0.265800:0.084848:0.265800:0.009762:0.003566:0.005914:0.003566
Severely compromised renal function, :@0.104091:0.277359:0.461568:0.277359:0.461568:0.261603:0.104091:0.261603:0.009583:0.012508:0.010660:0.012508:0.005713:0.012508:0.003848:0.010314:0.005330:0.012450:0.012604:0.018049:0.013123:0.005713:0.012604:0.018049:0.003848:0.007466:0.012508:0.013181:0.005330:0.005711:0.012508:0.011738:0.013143:0.003848:0.005330:0.006042:0.011699:0.011738:0.012450:0.006523:0.003848:0.012604:0.011738:0.005330:0.005330
glomerular filtration rate less than 60% :@0.104091:0.293829:0.458324:0.293829:0.458324:0.278073:0.104091:0.278073:0.012950:0.003848:0.012604:0.018049:0.012508:0.005792:0.011699:0.003848:0.013143:0.005792:0.005330:0.004686:0.004686:0.003848:0.006523:0.005792:0.013143:0.006523:0.003848:0.012604:0.011738:0.005330:0.005792:0.013143:0.006523:0.012508:0.005330:0.003848:0.012508:0.007466:0.007466:0.005330:0.006523:0.011738:0.013143:0.011738:0.005330:0.010660:0.010660:0.014913:0.005330
of age-adjusted normal values:@0.104091:0.310300:0.390337:0.310300:0.390337:0.294544:0.104091:0.294544:0.012604:0.006042:0.005330:0.013143:0.012950:0.012508:0.006388:0.013143:0.013181:0.003906:0.011699:0.007466:0.006523:0.012508:0.013181:0.005330:0.011738:0.012604:0.006308:0.018049:0.013143:0.003848:0.005330:0.010660:0.013143:0.003848:0.011699:0.012508:0.007466
n   :@0.084848:0.323656:0.107657:0.323656:0.107657:0.315216:0.084848:0.315216:0.009762:0.003566:0.005914:0.003566
Severely compromised bone-marrow :@0.104091:0.326775:0.454961:0.326775:0.454961:0.311019:0.104091:0.311019:0.009583:0.012508:0.010660:0.012508:0.005713:0.012508:0.003848:0.010314:0.005330:0.012450:0.012604:0.018049:0.013123:0.005713:0.012604:0.018049:0.003848:0.007466:0.012508:0.013181:0.005330:0.013123:0.012604:0.011738:0.012508:0.006388:0.018049:0.013143:0.005792:0.005703:0.012604:0.015990:0.005330
function; white blood cell (WBC) :@0.104091:0.343246:0.410699:0.343246:0.410699:0.327490:0.104091:0.327490:0.006042:0.011699:0.011738:0.012450:0.006523:0.003848:0.012604:0.011738:0.005330:0.005330:0.015990:0.011738:0.003848:0.006523:0.012508:0.005330:0.013123:0.003848:0.012604:0.012604:0.013181:0.005330:0.012450:0.012508:0.003848:0.003848:0.005330:0.007100:0.018473:0.011045:0.015644:0.007100:0.005330
<3,000/µL, with absolute neutrophil :@0.104091:0.359716:0.431108:0.359716:0.431108:0.343960:0.104091:0.343960:0.011661:0.010660:0.005330:0.010660:0.010660:0.010660:0.008409:0.011084:0.008890:0.005330:0.005330:0.015990:0.003848:0.006523:0.011738:0.005330:0.013143:0.013123:0.007466:0.012604:0.003848:0.011699:0.006523:0.012508:0.005330:0.011738:0.012508:0.011699:0.006523:0.005707:0.012604:0.013123:0.011738:0.003848:0.003848:0.005330
count <1,000/µL, platelet count :@0.104091:0.376186:0.400809:0.376186:0.400809:0.360430:0.104091:0.360430:0.012450:0.012604:0.011699:0.011738:0.006523:0.005330:0.011661:0.010660:0.005330:0.010660:0.010660:0.010660:0.008409:0.011084:0.008890:0.005330:0.005330:0.013123:0.003848:0.013143:0.006523:0.012508:0.003848:0.012508:0.006523:0.005330:0.012450:0.012604:0.011699:0.011738:0.006523:0.005330
<75,000/µL, red cell count <3,000,000/µL:@0.104091:0.392656:0.473824:0.392656:0.473824:0.376901:0.104091:0.376901:0.011661:0.010660:0.010660:0.005330:0.010660:0.010660:0.010660:0.008409:0.011084:0.008890:0.005330:0.005330:0.005725:0.012508:0.013181:0.005330:0.012450:0.012508:0.003848:0.003848:0.005330:0.012450:0.012604:0.011699:0.011738:0.006523:0.005330:0.011661:0.010660:0.005330:0.010660:0.010660:0.010660:0.005330:0.010660:0.010660:0.010660:0.008409:0.011084:0.008890
The following must be ensured before a :@0.084848:0.425597:0.481098:0.425597:0.481098:0.409841:0.084848:0.409841:0.008197:0.011738:0.012508:0.009198:0.006042:0.012604:0.003848:0.003848:0.012604:0.015990:0.003848:0.011738:0.012950:0.009198:0.018049:0.011699:0.007466:0.006523:0.009198:0.013123:0.012508:0.009198:0.012508:0.011738:0.007466:0.011699:0.005711:0.012508:0.013181:0.009198:0.013123:0.012508:0.006042:0.012604:0.005709:0.012508:0.009198:0.013143:0.005330
patient is planned for PRRNT::@0.084848:0.442067:0.351154:0.442067:0.351154:0.426311:0.084848:0.426311:0.013123:0.013143:0.006523:0.003848:0.012508:0.011738:0.006523:0.005330:0.003848:0.007466:0.005330:0.013123:0.003848:0.013143:0.011738:0.011738:0.012508:0.013181:0.005330:0.006042:0.012604:0.005792:0.005330:0.011392:0.011680:0.011680:0.014239:0.008226:0.005330
n   :@0.084848:0.455433:0.107657:0.455433:0.107657:0.446993:0.084848:0.446993:0.009762:0.003566:0.005914:0.003566
Histologically proven NET, ideally with :@0.104091:0.458552:0.452432:0.458552:0.452432:0.442796:0.104091:0.442796:0.013143:0.003848:0.007466:0.006523:0.012604:0.003848:0.012604:0.012950:0.003848:0.012450:0.013143:0.003848:0.003848:0.010314:0.005330:0.013123:0.005727:0.012604:0.010660:0.012508:0.011738:0.005330:0.014239:0.010314:0.006219:0.005330:0.005330:0.003848:0.013181:0.012508:0.013143:0.003848:0.003848:0.010314:0.005330:0.015990:0.003848:0.006523:0.011738:0.005330
Ki67 ≤20% (WHO grade 1 or 2):@0.104091:0.475023:0.379238:0.475023:0.379238:0.459267:0.104091:0.459267:0.011372:0.003848:0.010660:0.010660:0.005330:0.010564:0.010660:0.010660:0.014913:0.005330:0.007100:0.018473:0.013143:0.016722:0.005330:0.012950:0.005792:0.013143:0.013181:0.012508:0.005330:0.010660:0.005330:0.012604:0.005792:0.005330:0.010660:0.007100
n   :@0.084848:0.488377:0.107657:0.488377:0.107657:0.479937:0.084848:0.479937:0.009762:0.003566:0.005914:0.003566
High expression of SSTs type 2, as :@0.104091:0.491497:0.411378:0.491497:0.411378:0.475741:0.104091:0.475741:0.013143:0.003848:0.012950:0.011738:0.005330:0.012508:0.009236:0.013123:0.005711:0.012508:0.007466:0.007466:0.003848:0.012604:0.011738:0.005330:0.012604:0.006042:0.005330:0.009583:0.009583:0.007745:0.007466:0.005330:0.006523:0.010314:0.013123:0.012508:0.005330:0.010660:0.005330:0.005330:0.013143:0.007466:0.005330
demonstrated on a Ga-68 DOTATATE :@0.104091:0.507967:0.447227:0.507967:0.447227:0.492211:0.104091:0.492211:0.013181:0.012508:0.018049:0.012604:0.011738:0.007466:0.006523:0.005792:0.013143:0.006523:0.012508:0.013181:0.005330:0.012604:0.011738:0.005330:0.013143:0.005330:0.016779:0.013143:0.006388:0.010660:0.010660:0.005330:0.014316:0.016722:0.006623:0.012673:0.006635:0.012675:0.008197:0.010314:0.005330
PET/CT scan:@0.104091:0.524437:0.216370:0.524437:0.216370:0.508681:0.104091:0.508681:0.011392:0.010314:0.008197:0.008409:0.015644:0.008197:0.005330:0.007466:0.012450:0.013143:0.011738
n   :@0.084848:0.537794:0.107657:0.537794:0.107657:0.529353:0.084848:0.529353:0.009762:0.003566:0.005914:0.003566
Karnofsky performance status above :@0.104091:0.540913:0.453985:0.540913:0.453985:0.525157:0.104091:0.525157:0.011372:0.013143:0.006190:0.011738:0.012604:0.006042:0.007466:0.009660:0.010314:0.005330:0.013123:0.012508:0.006704:0.006042:0.012604:0.006319:0.018049:0.013143:0.011738:0.012450:0.012508:0.005330:0.007466:0.006523:0.013143:0.006523:0.011699:0.007466:0.005330:0.013143:0.013123:0.012604:0.010660:0.012508:0.005330
60% (ECOG <2):@0.104091:0.557383:0.246966:0.557383:0.246966:0.541627:0.104091:0.541627:0.010660:0.010660:0.014913:0.005330:0.007100:0.010314:0.015644:0.016722:0.016779:0.005330:0.011661:0.010660:0.007100
n   :@0.084848:0.570738:0.107657:0.570738:0.107657:0.562298:0.084848:0.562298:0.009762:0.003566:0.005914:0.003566
Renal scintigraphy documenting good :@0.104091:0.573857:0.469889:0.573857:0.469889:0.558101:0.104091:0.558101:0.011680:0.012508:0.011738:0.013143:0.003848:0.005330:0.007466:0.012450:0.003848:0.011738:0.006523:0.003848:0.012950:0.005792:0.013143:0.013123:0.011738:0.010314:0.005330:0.013181:0.012604:0.012450:0.011699:0.018049:0.012508:0.011738:0.006523:0.003848:0.011738:0.012950:0.005330:0.012950:0.012604:0.012604:0.013181:0.005330
renal function and absence of urinary :@0.104091:0.590327:0.461632:0.590327:0.461632:0.574571:0.104091:0.574571:0.005713:0.012508:0.011738:0.013143:0.003848:0.005330:0.006042:0.011699:0.011738:0.012450:0.006523:0.003848:0.012604:0.011738:0.005330:0.013143:0.011738:0.013181:0.005330:0.013143:0.013123:0.007466:0.012508:0.011738:0.012450:0.012508:0.005330:0.012604:0.006042:0.005330:0.011699:0.005792:0.003848:0.011738:0.013143:0.005792:0.010314:0.005330
tract obstruction:@0.104091:0.606798:0.258222:0.606798:0.258222:0.591042:0.104091:0.591042:0.006523:0.005792:0.013143:0.012450:0.006523:0.005330:0.012604:0.013123:0.007466:0.006523:0.005792:0.011699:0.012450:0.006523:0.003848:0.012604:0.011738
n   :@0.084848:0.620154:0.107657:0.620154:0.107657:0.611714:0.084848:0.611714:0.009762:0.003566:0.005914:0.003566
Absence of any contra-indication:@0.104091:0.623273:0.419512:0.623273:0.419512:0.607518:0.104091:0.607518:0.014239:0.013123:0.007466:0.012508:0.011738:0.012450:0.012508:0.005330:0.012604:0.006042:0.005330:0.013143:0.011738:0.010314:0.005330:0.012450:0.012604:0.011738:0.006523:0.005792:0.013143:0.006388:0.003848:0.011738:0.013181:0.003848:0.012450:0.013143:0.006523:0.003848:0.012604:0.011738
PRRNT  must be administered in a well-:@0.084848:0.656214:0.475762:0.656214:0.475762:0.640458:0.084848:0.640458:0.011392:0.011680:0.011680:0.014239:0.008197:0.005330:0.006542:0.018049:0.011699:0.007466:0.006523:0.011892:0.013123:0.012508:0.011892:0.013143:0.013181:0.018049:0.003848:0.011738:0.003848:0.007466:0.006523:0.012508:0.005719:0.012508:0.013181:0.011892:0.003848:0.011738:0.011892:0.013143:0.011892:0.015990:0.012508:0.003848:0.003848:0.006388
equipped specialised  facility with well-:@0.084848:0.672684:0.475731:0.672684:0.475731:0.656928:0.084848:0.656928:0.012508:0.013123:0.011699:0.003848:0.013123:0.013123:0.012508:0.013181:0.013412:0.007466:0.013123:0.012508:0.012450:0.003848:0.013143:0.003848:0.003848:0.007466:0.012508:0.013181:0.005330:0.008101:0.006042:0.013143:0.012450:0.003848:0.003848:0.003848:0.006523:0.010325:0.013412:0.015990:0.003848:0.006523:0.011738:0.013412:0.015990:0.012508:0.003848:0.003848:0.006388
trained  staff.  Therapy  is co-administered :@0.084848:0.689155:0.481096:0.689155:0.481096:0.673399:0.084848:0.673399:0.006523:0.005792:0.013143:0.003848:0.011738:0.012508:0.013181:0.005330:0.004741:0.007466:0.006523:0.013143:0.006100:0.006042:0.005330:0.005330:0.004741:0.008197:0.011738:0.012508:0.005792:0.013143:0.013123:0.010314:0.005330:0.004743:0.003848:0.007466:0.010083:0.012450:0.012604:0.006388:0.013143:0.013181:0.018049:0.003848:0.011738:0.003848:0.007466:0.006523:0.012508:0.005717:0.012508:0.013181:0.005330
with amino acid solution to prevent the re-:@0.084848:0.705625:0.475765:0.705625:0.475765:0.689869:0.084848:0.689869:0.015990:0.003848:0.006523:0.011738:0.004753:0.013143:0.018049:0.003848:0.011738:0.012604:0.004741:0.013143:0.012450:0.003848:0.013181:0.004753:0.007466:0.012604:0.003848:0.011699:0.006523:0.003848:0.012604:0.011738:0.004741:0.006523:0.012604:0.004737:0.013123:0.005715:0.012508:0.010660:0.012508:0.011738:0.006523:0.004739:0.006523:0.011738:0.012508:0.004737:0.005713:0.012508:0.006388
nal side effects of treatment. Anti-emetics :@0.084848:0.722095:0.481080:0.722095:0.481080:0.706339:0.084848:0.706339:0.011738:0.013143:0.003848:0.005657:0.007466:0.003848:0.013181:0.012508:0.005657:0.012508:0.006096:0.006042:0.012508:0.012450:0.006523:0.007466:0.005657:0.012604:0.006042:0.005657:0.006523:0.005711:0.012508:0.013143:0.006523:0.018049:0.012508:0.011738:0.006523:0.005330:0.005657:0.014239:0.011738:0.006523:0.003848:0.006388:0.012508:0.018049:0.012508:0.006523:0.003848:0.012450:0.007466:0.005330
and corticosteroids are given to  prevent :@0.084848:0.738566:0.481117:0.738566:0.481117:0.722810:0.084848:0.722810:0.013143:0.011738:0.013181:0.008467:0.012450:0.012604:0.005792:0.006523:0.003848:0.012450:0.012604:0.007466:0.006523:0.012508:0.005713:0.012604:0.003848:0.013181:0.007466:0.008467:0.013143:0.005715:0.012508:0.008467:0.012950:0.003848:0.010660:0.012508:0.011738:0.008467:0.006523:0.012604:0.005330:0.003127:0.013123:0.005717:0.012508:0.010660:0.012508:0.011738:0.006523:0.005330
the  side effects associated with amino :@0.084848:0.755036:0.481092:0.755036:0.481092:0.739280:0.084848:0.739280:0.006523:0.011738:0.012508:0.005330:0.006608:0.007466:0.003848:0.013181:0.012508:0.011950:0.012508:0.006096:0.006042:0.012508:0.012450:0.006523:0.007466:0.011950:0.013143:0.007466:0.007466:0.012604:0.012450:0.003848:0.013143:0.006523:0.012508:0.013181:0.011950:0.015990:0.003848:0.006523:0.011738:0.011950:0.013143:0.018049:0.003848:0.011738:0.012604:0.005330
acid infusion.:@0.084848:0.771506:0.207115:0.771506:0.207115:0.755750:0.084848:0.755750:0.013143:0.012450:0.003848:0.013181:0.005330:0.003848:0.011738:0.006042:0.011699:0.007466:0.003848:0.012604:0.011738:0.005330
The results of NETTER-1 trial; a multicen-:@0.103032:0.787977:0.475787:0.787977:0.475787:0.772221:0.103032:0.772221:0.008197:0.011738:0.012508:0.007951:0.005713:0.012508:0.007466:0.011699:0.003848:0.006523:0.007466:0.007966:0.012604:0.006042:0.007955:0.014239:0.010314:0.008197:0.008197:0.010314:0.011680:0.006388:0.010660:0.007966:0.006523:0.005792:0.003848:0.013143:0.003848:0.005330:0.007966:0.013143:0.007966:0.018049:0.011699:0.003848:0.006523:0.003848:0.012450:0.012508:0.011738:0.006388
tre,  randomised,  controlled trial of  the :@0.084848:0.804447:0.481109:0.804447:0.481109:0.788691:0.084848:0.788691:0.006523:0.005709:0.012508:0.005330:0.005330:0.007953:0.005792:0.013143:0.011738:0.013181:0.012604:0.018049:0.003848:0.007466:0.012508:0.013181:0.005330:0.005330:0.007955:0.012450:0.012604:0.011738:0.006523:0.005703:0.012604:0.003848:0.003848:0.012508:0.013181:0.013297:0.006523:0.005792:0.003848:0.013143:0.003848:0.013297:0.012604:0.006042:0.005330:0.007953:0.006523:0.011738:0.012508:0.005330
efficacy  and  safety  of  Lu-177  DOTATATE :@0.084848:0.820917:0.481088:0.820917:0.481088:0.805161:0.084848:0.805161:0.012508:0.006042:0.004686:0.004686:0.012450:0.013143:0.012450:0.010314:0.005330:0.005626:0.013143:0.011738:0.013181:0.005330:0.005630:0.007466:0.013143:0.006042:0.012508:0.006523:0.010314:0.005330:0.005632:0.012604:0.006042:0.005330:0.005623:0.008890:0.011699:0.006388:0.010660:0.010660:0.010660:0.005330:0.005638:0.014316:0.016722:0.006639:0.012675:0.006633:0.012675:0.008197:0.010314:0.005330
in patients with advanced, progressive, :@0.084848:0.837388:0.481059:0.837388:0.481059:0.821632:0.084848:0.821632:0.003848:0.011738:0.011776:0.013123:0.013143:0.006523:0.003848:0.012508:0.011738:0.006523:0.007466:0.011776:0.015990:0.003848:0.006523:0.011738:0.011776:0.013143:0.013181:0.010660:0.013143:0.011738:0.012450:0.012508:0.013181:0.005330:0.011776:0.013123:0.005715:0.012604:0.012950:0.005705:0.012508:0.007466:0.007466:0.003848:0.010660:0.012508:0.005330:0.005330
SSTR-expressing midgut NETs, was recently :@0.084848:0.853858:0.481101:0.853858:0.481101:0.838102:0.084848:0.838102:0.009583:0.009583:0.008197:0.011680:0.006388:0.012508:0.009236:0.013123:0.005709:0.012508:0.007466:0.007466:0.003848:0.011738:0.012950:0.006350:0.018049:0.003848:0.013181:0.012950:0.011699:0.006523:0.006340:0.014239:0.010314:0.007749:0.007466:0.005330:0.006350:0.015990:0.013143:0.007466:0.006350:0.005711:0.012508:0.012450:0.012508:0.011738:0.006523:0.003848:0.010314:0.005330
reported.  Patients were randomised to :@0.084848:0.870328:0.481119:0.870328:0.481119:0.854572:0.084848:0.854572:0.005713:0.012508:0.013123:0.012604:0.005792:0.006523:0.012508:0.013181:0.005330:0.005330:0.007945:0.011392:0.013143:0.006523:0.003848:0.012508:0.011738:0.006523:0.007466:0.013297:0.015990:0.012508:0.005711:0.012508:0.013297:0.005792:0.013143:0.011738:0.013181:0.012604:0.018049:0.003848:0.007466:0.012508:0.013181:0.013297:0.006523:0.012604:0.005330
either receive four cycles of Lu-177 DOTA-:@0.084848:0.886798:0.475769:0.886798:0.475769:0.871043:0.084848:0.871043:0.012508:0.003848:0.006523:0.011738:0.012508:0.005792:0.006119:0.005713:0.012508:0.012450:0.012508:0.003848:0.010660:0.012508:0.006119:0.006042:0.012604:0.011699:0.005792:0.006119:0.012450:0.010314:0.012450:0.003848:0.012508:0.007466:0.006119:0.012604:0.006042:0.006119:0.008890:0.011699:0.006388:0.010660:0.010660:0.010660:0.006133:0.014316:0.016722:0.006639:0.014239:0.006388
TATE  plus a monthly  intramuscular  injec-:@0.084848:0.903269:0.475765:0.903269:0.475765:0.887513:0.084848:0.887513:0.006633:0.012675:0.008197:0.010314:0.005330:0.005261:0.013123:0.003848:0.011699:0.007466:0.010603:0.013143:0.010603:0.018049:0.012604:0.011738:0.006523:0.011738:0.003848:0.010314:0.005330:0.005257:0.003848:0.011738:0.006523:0.005792:0.013143:0.018049:0.011699:0.007466:0.012450:0.011699:0.003848:0.013143:0.005792:0.005330:0.005261:0.003848:0.011738:0.003906:0.012508:0.012450:0.006388
tion of 30 mg octreotide (Lu-177 DOTATATE :@0.084848:0.919739:0.481099:0.919739:0.481099:0.903983:0.084848:0.903983:0.006523:0.003848:0.012604:0.011738:0.005426:0.012604:0.006042:0.005426:0.010660:0.010660:0.005426:0.018049:0.012950:0.005426:0.012604:0.012450:0.006523:0.005705:0.012508:0.012604:0.006523:0.003848:0.013181:0.012508:0.005426:0.007100:0.008890:0.011699:0.006388:0.010660:0.010660:0.010660:0.005426:0.014316:0.016722:0.006639:0.012675:0.006633:0.012675:0.008197:0.010314:0.005330
group, n = 111) or a monthly injection of :@0.084848:0.936209:0.481090:0.936209:0.481090:0.920453:0.084848:0.920453:0.012950:0.005709:0.012604:0.011699:0.013123:0.005330:0.007853:0.011738:0.007855:0.011661:0.007851:0.010660:0.010660:0.010672:0.007100:0.007861:0.012604:0.005792:0.007851:0.013143:0.007861:0.018049:0.012604:0.011738:0.006523:0.011738:0.003848:0.010314:0.007857:0.003848:0.011738:0.003906:0.012508:0.012450:0.006523:0.003848:0.012604:0.011738:0.007855:0.012604:0.006042:0.005330
60  mg  intramuscular injection  of  octreo-:@0.524229:0.096131:0.915152:0.096131:0.915152:0.080375:0.524229:0.080375:0.010660:0.010660:0.005330:0.004041:0.018049:0.012950:0.005330:0.004031:0.003848:0.011738:0.006523:0.005792:0.013143:0.018049:0.011699:0.007466:0.012450:0.011699:0.003848:0.013143:0.005792:0.009371:0.003848:0.011738:0.003906:0.012508:0.012450:0.006523:0.003848:0.012604:0.011738:0.005330:0.004027:0.012604:0.006042:0.005330:0.004029:0.012604:0.012450:0.006523:0.005705:0.012508:0.012604:0.006388
tide LAR alone (control group, n  =  110). :@0.524229:0.112429:0.920454:0.112429:0.920454:0.096673:0.524229:0.096673:0.006523:0.003848:0.013181:0.012508:0.009198:0.008890:0.014239:0.011680:0.009198:0.013143:0.003848:0.012604:0.011738:0.012508:0.009198:0.007100:0.012450:0.012604:0.011738:0.006523:0.005705:0.012604:0.003848:0.009198:0.012950:0.005709:0.012604:0.011699:0.013123:0.005330:0.009198:0.011738:0.005330:0.003868:0.011661:0.005330:0.003868:0.010660:0.010660:0.010660:0.007100:0.005330:0.005330
The primary endpoint was progression-:@0.524229:0.128728:0.915129:0.128728:0.915129:0.112972:0.524229:0.112972:0.008197:0.011738:0.012508:0.013604:0.013123:0.005792:0.003848:0.018049:0.013143:0.005792:0.010314:0.013604:0.012508:0.011738:0.013181:0.013123:0.012604:0.003848:0.011738:0.006523:0.013604:0.015990:0.013143:0.007466:0.013604:0.013123:0.005715:0.012604:0.012950:0.005705:0.012508:0.007466:0.007466:0.003848:0.012604:0.011738:0.006388
free survival.  Progression-free survival  at :@0.524229:0.145026:0.920473:0.145026:0.920473:0.129270:0.524229:0.129270:0.006042:0.005711:0.012508:0.012508:0.011930:0.007466:0.011699:0.005792:0.010660:0.003848:0.010660:0.013143:0.003848:0.005330:0.005330:0.006619:0.011392:0.005713:0.012604:0.012950:0.005705:0.012508:0.007466:0.007466:0.003848:0.012604:0.011738:0.006388:0.006042:0.005715:0.012508:0.012508:0.011930:0.007466:0.011699:0.005792:0.010660:0.003848:0.010660:0.013143:0.003848:0.005330:0.006619:0.013143:0.006523:0.005330
20 months was 65.2% [95% CI, 50.0-76.8] in :@0.524229:0.161324:0.920440:0.161324:0.920440:0.145568:0.524229:0.145568:0.010660:0.010660:0.005850:0.018049:0.012604:0.011738:0.006523:0.011738:0.007466:0.005840:0.015990:0.013143:0.007466:0.005850:0.010660:0.010660:0.005330:0.010660:0.014913:0.005850:0.006754:0.010660:0.010660:0.014913:0.005850:0.015644:0.004349:0.005330:0.005850:0.010660:0.010660:0.005330:0.010660:0.006388:0.010660:0.010660:0.005330:0.010660:0.006754:0.005869:0.003848:0.011738:0.005330
the  Lu-177 DOTATATE  group :@0.524229:0.177623:0.793003:0.177623:0.793003:0.161867:0.524229:0.161867:0.006523:0.011738:0.012508:0.005330:0.004483:0.008890:0.011699:0.006388:0.010660:0.010660:0.010660:0.009833:0.014316:0.016722:0.006633:0.012675:0.006633:0.012675:0.008197:0.010314:0.005330:0.004489:0.012950:0.005709:0.012604:0.011699:0.013123:0.005330
versus:@0.797491:0.177623:0.853082:0.177623:0.853082:0.161867:0.797491:0.161867:0.010660:0.012508:0.005792:0.007466:0.011699:0.007466
  10.8% :@0.853082:0.177623:0.920456:0.177623:0.920456:0.161867:0.853082:0.161867:0.005330:0.004489:0.010660:0.010660:0.005330:0.010660:0.014913:0.005330
[95% CI, 3.5-23.0] in the control group. The :@0.524229:0.193921:0.920484:0.193921:0.920484:0.178165:0.524229:0.178165:0.006754:0.010660:0.010660:0.014913:0.005696:0.015644:0.004349:0.005330:0.005684:0.010660:0.005330:0.010660:0.006388:0.010660:0.010660:0.005330:0.010660:0.006754:0.005696:0.003848:0.011738:0.005696:0.006523:0.011738:0.012508:0.005680:0.012450:0.012604:0.011738:0.006523:0.005702:0.012604:0.003848:0.005696:0.012950:0.005709:0.012604:0.011699:0.013123:0.005330:0.005680:0.008197:0.011738:0.012508:0.005330
median  progression-free  survival had  not :@0.524229:0.210219:0.920477:0.210219:0.920477:0.194463:0.524229:0.194463:0.018049:0.012508:0.013181:0.003848:0.013143:0.011738:0.005330:0.003048:0.013123:0.005715:0.012604:0.012950:0.005705:0.012508:0.007466:0.007466:0.003848:0.012604:0.011738:0.006388:0.006042:0.005717:0.012508:0.012508:0.005330:0.003042:0.007466:0.011699:0.005792:0.010660:0.003848:0.010660:0.013143:0.003848:0.008390:0.011738:0.013143:0.013181:0.005330:0.003046:0.011738:0.012604:0.006523:0.005330
yet been reached in the Lu-177 DOTATATE :@0.524229:0.226518:0.920459:0.226518:0.920459:0.210762:0.524229:0.210762:0.010314:0.012508:0.006523:0.006158:0.013123:0.012508:0.012508:0.011738:0.006158:0.005711:0.012508:0.013143:0.012450:0.011738:0.012508:0.013181:0.006158:0.003848:0.011738:0.006158:0.006523:0.011738:0.012508:0.006158:0.008890:0.011699:0.006388:0.010660:0.010660:0.010660:0.006169:0.014316:0.016722:0.006639:0.012675:0.006633:0.012675:0.008197:0.010314:0.005330
group and was 8.4 months in the control :@0.524229:0.242816:0.920484:0.242816:0.920484:0.227060:0.524229:0.227060:0.012950:0.005709:0.012604:0.011699:0.013123:0.007658:0.013143:0.011738:0.013181:0.007658:0.015990:0.013143:0.007466:0.007658:0.010660:0.005330:0.010660:0.007658:0.018049:0.012604:0.011738:0.006523:0.011738:0.007466:0.007645:0.003848:0.011738:0.007658:0.006523:0.011738:0.012508:0.007647:0.012450:0.012604:0.011738:0.006523:0.005703:0.012604:0.003848:0.005330
group. There was 60% lower risk of death :@0.524229:0.259114:0.920481:0.259114:0.920481:0.243358:0.524229:0.243358:0.012950:0.005709:0.012604:0.011699:0.013123:0.005330:0.007531:0.008197:0.011738:0.012508:0.005705:0.012508:0.007543:0.015990:0.013143:0.007466:0.007543:0.010660:0.010660:0.014913:0.007543:0.003848:0.012604:0.015990:0.012508:0.005792:0.007533:0.005792:0.003848:0.007466:0.009660:0.007543:0.012604:0.006042:0.007533:0.013181:0.012508:0.013143:0.006523:0.011738:0.005330
in the Lu-177 DOTATATE group than in the :@0.524229:0.275413:0.920482:0.275413:0.920482:0.259657:0.524229:0.259657:0.003848:0.011738:0.007408:0.006523:0.011738:0.012508:0.007408:0.008890:0.011699:0.006388:0.010660:0.010660:0.010660:0.007408:0.014316:0.016722:0.006637:0.012675:0.006633:0.012675:0.008197:0.010314:0.007408:0.012950:0.005709:0.012604:0.011699:0.013123:0.007408:0.006523:0.011738:0.013143:0.011738:0.007408:0.003848:0.011738:0.007408:0.006523:0.011738:0.012508:0.005330
control. Eighteen  patients in the  Lu-177 :@0.524229:0.291711:0.920471:0.291711:0.920471:0.275955:0.524229:0.275955:0.012450:0.012604:0.011738:0.006523:0.005703:0.012604:0.003848:0.005330:0.011565:0.010314:0.003848:0.012950:0.011738:0.006523:0.012508:0.012508:0.011738:0.005330:0.006221:0.013123:0.013143:0.006523:0.003848:0.012508:0.011738:0.006523:0.007466:0.011565:0.003848:0.011738:0.011565:0.006523:0.011738:0.012508:0.005330:0.006223:0.008890:0.011699:0.006388:0.010660:0.010660:0.010660:0.005330
DOTATATE group had either  complete or :@0.524229:0.308009:0.920494:0.308009:0.920494:0.292253:0.524229:0.292253:0.014316:0.016722:0.006639:0.012675:0.006633:0.012675:0.008197:0.010314:0.009140:0.012950:0.005711:0.012604:0.011699:0.013123:0.009140:0.011738:0.013143:0.013181:0.009140:0.012508:0.003848:0.006523:0.011738:0.012508:0.005792:0.005330:0.003798:0.012450:0.012604:0.018049:0.013123:0.003848:0.012508:0.006523:0.012508:0.009140:0.012604:0.005792:0.005330
partial response, compared with three in :@0.524229:0.324308:0.920469:0.324308:0.920469:0.308552:0.524229:0.308552:0.013123:0.013143:0.005792:0.006523:0.003848:0.013143:0.003848:0.007928:0.005713:0.012508:0.007466:0.013123:0.012604:0.011738:0.007466:0.012508:0.005330:0.007914:0.012450:0.012604:0.018049:0.013123:0.013143:0.005713:0.012508:0.013181:0.007918:0.015990:0.003848:0.006523:0.011738:0.007918:0.006523:0.011738:0.005707:0.012508:0.012508:0.007914:0.003848:0.011738:0.005330
the control arm. Side effects requiring dis-:@0.524229:0.340606:0.915139:0.340606:0.915139:0.324850:0.524229:0.324850:0.006523:0.011738:0.012508:0.006161:0.012450:0.012604:0.011738:0.006523:0.005711:0.012604:0.003848:0.006167:0.013143:0.006325:0.018049:0.005330:0.006165:0.009583:0.003848:0.013181:0.012508:0.006177:0.012508:0.006094:0.006042:0.012508:0.012450:0.006523:0.007466:0.006167:0.005713:0.012508:0.013123:0.011699:0.003848:0.005792:0.003848:0.011738:0.012950:0.006163:0.013181:0.003848:0.007466:0.006388
continuation of treatment occurred in 6% :@0.524229:0.356904:0.920490:0.356904:0.920490:0.341148:0.524229:0.341148:0.012450:0.012604:0.011738:0.006523:0.003848:0.011738:0.011699:0.013143:0.006523:0.003848:0.012604:0.011738:0.006598:0.012604:0.006042:0.006619:0.006523:0.005711:0.012508:0.013143:0.006523:0.018049:0.012508:0.011738:0.006523:0.006602:0.012604:0.012450:0.012450:0.011699:0.005792:0.005702:0.012508:0.013181:0.006619:0.003848:0.011738:0.006619:0.010660:0.014913:0.005330
in the Lu-177 DOTATATE group, compared :@0.524229:0.373203:0.920477:0.373203:0.920477:0.357447:0.524229:0.357447:0.003848:0.011738:0.007050:0.006523:0.011738:0.012508:0.007041:0.008890:0.011699:0.006388:0.010660:0.010660:0.010660:0.007062:0.014316:0.016722:0.006639:0.012675:0.006633:0.012675:0.008197:0.010314:0.007047:0.012950:0.005711:0.012604:0.011699:0.013123:0.005330:0.007047:0.012450:0.012604:0.018049:0.013123:0.013143:0.005711:0.012508:0.013181:0.005330
with 9% in the control. The  commonest :@0.524229:0.389501:0.920504:0.389501:0.920504:0.373745:0.524229:0.373745:0.015990:0.003848:0.006523:0.011738:0.010949:0.010660:0.014913:0.010949:0.003848:0.011738:0.010949:0.006523:0.011738:0.012508:0.010949:0.012450:0.012604:0.011738:0.006523:0.005703:0.012604:0.003848:0.005330:0.010949:0.008197:0.011738:0.012508:0.005330:0.005607:0.012450:0.012604:0.018049:0.018049:0.012604:0.011738:0.012508:0.007466:0.006523:0.005330
side effects in the Lu-177 DOTATATE group :@0.524229:0.405799:0.920481:0.405799:0.920481:0.390043:0.524229:0.390043:0.007466:0.003848:0.013181:0.012508:0.006793:0.012508:0.006096:0.006042:0.012508:0.012450:0.006523:0.007466:0.006793:0.003848:0.011738:0.006793:0.006523:0.011738:0.012508:0.006793:0.008890:0.011699:0.006388:0.010660:0.010660:0.010660:0.006793:0.014316:0.016722:0.006639:0.012675:0.006633:0.012675:0.008197:0.010314:0.006793:0.012950:0.005709:0.012604:0.011699:0.013123:0.005330
were nausea and vomiting related to :@0.524229:0.422098:0.920463:0.422098:0.920463:0.406342:0.524229:0.406342:0.015990:0.012508:0.005711:0.012508:0.013932:0.011738:0.013143:0.011699:0.007466:0.012508:0.013143:0.013932:0.013143:0.011738:0.013181:0.013932:0.010660:0.012604:0.018049:0.003848:0.006523:0.003848:0.011738:0.012950:0.013932:0.005713:0.012508:0.003848:0.013143:0.006523:0.012508:0.013181:0.013932:0.006523:0.012604:0.005330
amino acid infusion. Grade 3 and 4 side :@0.524229:0.438396:0.920477:0.438396:0.920477:0.422640:0.524229:0.422640:0.013143:0.018049:0.003848:0.011738:0.012604:0.008111:0.013143:0.012450:0.003848:0.013181:0.008120:0.003848:0.011738:0.006042:0.011699:0.007466:0.003848:0.012604:0.011738:0.005330:0.008109:0.016779:0.005792:0.013143:0.013181:0.012508:0.008111:0.010660:0.008120:0.013143:0.011738:0.013181:0.008120:0.010660:0.008120:0.007466:0.003848:0.013181:0.012508:0.005330
effects  were  similar in  both  groups.  No :@0.524229:0.454694:0.920477:0.454694:0.920477:0.438938:0.524229:0.438938:0.012508:0.006096:0.006042:0.012508:0.012450:0.006523:0.007466:0.005330:0.006219:0.015990:0.012508:0.005711:0.012508:0.005330:0.006221:0.007466:0.003848:0.018049:0.003848:0.003848:0.013143:0.005792:0.011565:0.003848:0.011738:0.005330:0.006223:0.013123:0.012604:0.006523:0.011738:0.005330:0.006215:0.012950:0.005709:0.012604:0.011699:0.013123:0.007466:0.005330:0.005330:0.006219:0.014239:0.012604:0.005330
renal toxicity was  seen.  Response rate :@0.524229:0.470993:0.920479:0.471047:0.920479:0.455291:0.524229:0.455237:0.005713:0.012508:0.011738:0.013143:0.003848:0.011834:0.006523:0.012604:0.009236:0.003848:0.012450:0.003848:0.006523:0.010314:0.011834:0.015990:0.013143:0.007466:0.005330:0.006515:0.007466:0.012508:0.012508:0.011738:0.005330:0.006235:0.011834:0.011680:0.012508:0.007466:0.013123:0.012604:0.011738:0.007466:0.012508:0.011834:0.005792:0.013143:0.006523:0.012508:-0.122846
3:@0.758206:0.465428:0.764421:0.465428:0.764421:0.456242:0.758206:0.456242:0.006215
to Lu-177 DOTATATE demonstrated in this :@0.524240:0.487345:0.920481:0.487345:0.920481:0.471589:0.524240:0.471589:0.006523:0.012604:0.009256:0.008890:0.011699:0.006388:0.010660:0.010660:0.010660:0.009256:0.014316:0.016722:0.006639:0.012675:0.006635:0.012673:0.008197:0.010314:0.009256:0.013181:0.012508:0.018049:0.012604:0.011738:0.007466:0.006523:0.005792:0.013143:0.006523:0.012508:0.013181:0.009256:0.003848:0.011738:0.009256:0.006523:0.011738:0.003848:0.007466:0.005330
study was higher compared with response :@0.524240:0.503644:0.920464:0.503644:0.920464:0.487888:0.524240:0.487888:0.007466:0.006523:0.011699:0.013181:0.010314:0.004907:0.015990:0.013143:0.007466:0.004918:0.011738:0.003848:0.012950:0.011738:0.012508:0.005792:0.004907:0.012450:0.012604:0.018049:0.013123:0.013143:0.005711:0.012508:0.013181:0.004907:0.015990:0.003848:0.006523:0.011738:0.004907:0.005711:0.012508:0.007466:0.013123:0.012604:0.011738:0.007466:0.012508:0.005330
rates reported in other studies, with similar :@0.524240:0.519942:0.920477:0.519942:0.920477:0.504186:0.524240:0.504186:0.005792:0.013143:0.006523:0.012508:0.007466:0.006109:0.005713:0.012508:0.013123:0.012604:0.005792:0.006523:0.012508:0.013181:0.006104:0.003848:0.011738:0.006119:0.012604:0.006523:0.011738:0.012508:0.005792:0.006096:0.007466:0.006523:0.011699:0.013181:0.003848:0.012508:0.007466:0.005330:0.006109:0.015990:0.003848:0.006523:0.011738:0.006119:0.007466:0.003848:0.018049:0.003848:0.003848:0.013143:0.005792:0.005330
patients using other treatment options, in-:@0.524240:0.536240:0.915159:0.536240:0.915159:0.520484:0.524240:0.520484:0.013123:0.013143:0.006523:0.003848:0.012508:0.011738:0.006523:0.007466:0.006158:0.011699:0.007466:0.003848:0.011738:0.012950:0.006158:0.012604:0.006523:0.011738:0.012508:0.005792:0.006140:0.006523:0.005709:0.012508:0.013143:0.006523:0.018049:0.012508:0.011738:0.006523:0.006144:0.012604:0.013123:0.006523:0.003848:0.012604:0.011738:0.007466:0.005330:0.006146:0.003848:0.011738:0.006388
cluding everolimus, alpha-interferon  and :@0.524240:0.552539:0.920473:0.552539:0.920473:0.536783:0.524240:0.536783:0.012450:0.003848:0.011699:0.013181:0.003848:0.011738:0.012950:0.009198:0.012508:0.010660:0.012508:0.005713:0.012604:0.003848:0.003848:0.018049:0.011699:0.007466:0.005330:0.009198:0.013143:0.003848:0.013123:0.011738:0.013143:0.006388:0.003848:0.011738:0.006523:0.012508:0.006708:0.006042:0.012508:0.005709:0.012604:0.011738:0.005330:0.003858:0.013143:0.011738:0.013181:0.005330
lanreotide.:@0.524240:0.568837:0.625185:0.568837:0.625185:0.553081:0.524240:0.553081:0.003848:0.013143:0.011738:0.005715:0.012508:0.012604:0.006523:0.003848:0.013181:0.012508:0.005330
4-6:@0.625180:0.563223:0.641334:0.563223:0.641334:0.554037:0.625180:0.554037:0.006215:0.003724:0.006215
In a report of the long-term toxicity of :@0.542424:0.585141:0.920477:0.585141:0.920477:0.569385:0.542424:0.569385:0.004349:0.011738:0.008986:0.013143:0.008986:0.005711:0.012508:0.013123:0.012604:0.005792:0.006523:0.008986:0.012604:0.006042:0.008986:0.006523:0.011738:0.012508:0.008986:0.003848:0.012604:0.011738:0.012950:0.006388:0.006523:0.012508:0.006313:0.018049:0.008986:0.006523:0.012604:0.009236:0.003848:0.012450:0.003848:0.006523:0.010314:0.008986:0.012604:0.006042:0.005330
PRRNT in 807 patients with NETs, Bodei:@0.524240:0.601440:0.883551:0.601440:0.883551:0.585684:0.524240:0.585684:0.011392:0.011680:0.011680:0.014239:0.008197:0.007204:0.003848:0.011738:0.007216:0.010660:0.010660:0.010660:0.007231:0.013123:0.013143:0.006523:0.003848:0.012508:0.011738:0.006523:0.007466:0.007216:0.015990:0.003848:0.006523:0.011738:0.007216:0.014239:0.010314:0.007749:0.007466:0.005330:0.007216:0.011045:0.012604:0.013181:0.012508:0.003848
, et :@0.883551:0.601440:0.920458:0.601440:0.920458:0.585684:0.883551:0.585684:0.005330:0.007216:0.012508:0.006523:0.005330
al:@0.524240:0.617738:0.541231:0.617738:0.541231:0.601982:0.524240:0.601982:0.013143:0.003848
 reported grade 3/4 renal toxicity in 1.5% :@0.541231:0.617738:0.920485:0.617738:0.920485:0.601982:0.541231:0.601982:0.005030:0.005713:0.012508:0.013123:0.012604:0.005792:0.006523:0.012508:0.013181:0.005022:0.012950:0.005792:0.013143:0.013181:0.012508:0.005036:0.010660:0.008409:0.010660:0.005042:0.005711:0.012508:0.011738:0.013143:0.003848:0.005032:0.006523:0.012604:0.009236:0.003848:0.012450:0.003848:0.006523:0.010314:0.005032:0.003848:0.011738:0.005032:0.010660:0.005330:0.010660:0.014913:0.005330
of  patients,  grade  3/4 bone-marrow  tox-:@0.524240:0.634036:0.915165:0.634036:0.915165:0.618280:0.524240:0.618280:0.012604:0.006042:0.005330:0.003140:0.013123:0.013143:0.006523:0.003848:0.012508:0.011738:0.006523:0.007466:0.005330:0.005330:0.003144:0.012950:0.005792:0.013143:0.013181:0.012508:0.005330:0.003144:0.010660:0.008409:0.010660:0.008486:0.013123:0.012604:0.011738:0.012508:0.006388:0.018049:0.013143:0.005792:0.005705:0.012604:0.015990:0.005330:0.003142:0.006523:0.012604:0.009236:0.006388
icity in 9.5% of  patients,  myelodysplastic :@0.524240:0.650335:0.920479:0.650335:0.920479:0.634579:0.524240:0.634579:0.003848:0.012450:0.003848:0.006523:0.010314:0.009852:0.003848:0.011738:0.009852:0.010660:0.005330:0.010660:0.014913:0.009852:0.012604:0.006042:0.005330:0.004512:0.013123:0.013143:0.006523:0.003848:0.012508:0.011738:0.006523:0.007466:0.005330:0.005330:0.004512:0.018049:0.010314:0.012508:0.003848:0.012604:0.013181:0.010314:0.007466:0.013123:0.003848:0.013143:0.007466:0.006523:0.003848:0.012450:0.005330
syndrome in 2.35% and eight patients with :@0.524240:0.666633:0.920462:0.666633:0.920462:0.650877:0.524240:0.650877:0.007466:0.010314:0.011738:0.013181:0.005717:0.012604:0.018049:0.012508:0.005484:0.003848:0.011738:0.005484:0.010660:0.005330:0.010660:0.010660:0.014913:0.005484:0.013143:0.011738:0.013181:0.005484:0.012508:0.003848:0.012950:0.011738:0.006523:0.005484:0.013123:0.013143:0.006523:0.003848:0.012508:0.011738:0.006523:0.007466:0.005484:0.015990:0.003848:0.006523:0.011738:0.005330
acute leukaemia, six of whom converted :@0.524240:0.682931:0.920479:0.682931:0.920479:0.667175:0.524240:0.667175:0.013143:0.012450:0.011699:0.006523:0.012508:0.007062:0.003848:0.012508:0.011699:0.009660:0.013143:0.012508:0.018049:0.003848:0.013143:0.005330:0.007062:0.007466:0.003848:0.009236:0.007062:0.012604:0.006042:0.007062:0.015990:0.011738:0.012604:0.018049:0.007062:0.012450:0.012604:0.011738:0.010660:0.012508:0.005792:0.006523:0.012508:0.013181:0.005330
from myelodysplastic syndrome.:@0.524240:0.699230:0.822911:0.699230:0.822911:0.683474:0.524240:0.683474:0.006042:0.005711:0.012604:0.018049:0.005330:0.018049:0.010314:0.012508:0.003848:0.012604:0.013181:0.010314:0.007466:0.013123:0.003848:0.013143:0.007466:0.006523:0.003848:0.012450:0.005330:0.007466:0.010314:0.011738:0.013181:0.005728:0.012604:0.018049:0.012508:0.005330
7:@0.822903:0.693617:0.829118:0.693617:0.829118:0.684431:0.822903:0.684431:0.006215
PROSTATE-SPECIFIC MEMBRANE :@0.524242:0.732481:0.883134:0.732481:0.883134:0.712884:0.524242:0.712884:0.013170:0.013641:0.019756:0.012230:0.009878:0.017404:0.009878:0.012230:0.009878:0.012230:0.013170:0.012230:0.018344:0.006585:0.011289:0.006585:0.018344:0.006585:0.021167:0.012230:0.021167:0.013641:0.013641:0.017404:0.017404:0.012230:0.006585
ANTIGEN RADIOLIGAND THERAPY :@0.524242:0.751722:0.903360:0.751722:0.903360:0.732125:0.524242:0.732125:0.017404:0.017404:0.009878:0.006585:0.019756:0.012230:0.017404:0.006585:0.013641:0.017404:0.016463:0.006585:0.019756:0.010348:0.006585:0.019756:0.017404:0.017404:0.016463:0.006585:0.009878:0.015993:0.012230:0.013641:0.017404:0.013170:0.014581:0.006585
(PRLT):@0.524242:0.770963:0.589153:0.770963:0.589153:0.751366:0.524242:0.751366:0.008937:0.013170:0.013641:0.010348:0.009878:0.008937
Prostate-specific :@0.524242:0.789551:0.683044:0.789551:0.683044:0.773795:0.524242:0.773795:0.011392:0.005709:0.012604:0.007466:0.006523:0.013143:0.006523:0.012508:0.006388:0.007466:0.013123:0.012508:0.012450:0.003848:0.004686:0.004686:0.012450:0.005330
membrane :@0.707759:0.789551:0.817998:0.789551:0.817998:0.773795:0.707759:0.773795:0.018049:0.012508:0.018049:0.013123:0.005792:0.013143:0.011738:0.012508:0.005330
antigen :@0.842713:0.789551:0.920491:0.789551:0.920491:0.773795:0.842713:0.773795:0.013143:0.011738:0.006523:0.003848:0.012950:0.012508:0.011738:0.005330
(PSMA) is a transmembrane glycoprotein :@0.524242:0.805849:0.920484:0.805849:0.920484:0.790093:0.524242:0.790093:0.007100:0.011392:0.009583:0.017684:0.014239:0.007100:0.007889:0.003848:0.007466:0.007889:0.013143:0.007889:0.006523:0.005792:0.013143:0.011738:0.007466:0.018049:0.012508:0.018049:0.013123:0.005792:0.013143:0.011738:0.012508:0.007889:0.012950:0.003848:0.010314:0.012450:0.012604:0.013123:0.005717:0.012604:0.006523:0.012508:0.003848:0.011738:0.005330
expressed on  the  cancer  cells in  meta-:@0.524242:0.822148:0.915163:0.822148:0.915163:0.806392:0.524242:0.806392:0.012508:0.009236:0.013123:0.005713:0.012508:0.007466:0.007466:0.012508:0.013181:0.010295:0.012604:0.011738:0.005330:0.004947:0.006523:0.011738:0.012508:0.005330:0.004947:0.012450:0.013143:0.011738:0.012450:0.012508:0.005792:0.005330:0.004945:0.012450:0.012508:0.003848:0.003848:0.007466:0.010295:0.003848:0.011738:0.005330:0.004955:0.018049:0.012508:0.006523:0.013143:0.006388
static prostate carcinoma. Its level  of :@0.524242:0.838446:0.920472:0.838446:0.920472:0.822690:0.524242:0.822690:0.007466:0.006523:0.013143:0.006523:0.003848:0.012450:0.014913:0.013123:0.005713:0.012604:0.007466:0.006523:0.013143:0.006523:0.012508:0.014913:0.012450:0.013143:0.005657:0.012450:0.003848:0.011738:0.012604:0.018049:0.013143:0.005330:0.014913:0.004349:0.006523:0.007466:0.014913:0.003848:0.012508:0.010660:0.012508:0.003848:0.005330:0.009594:0.012604:0.006042:0.005330
expression is even  higher  in metastatic :@0.524242:0.854744:0.920491:0.854744:0.920491:0.838988:0.524242:0.838988:0.012508:0.009236:0.013123:0.005713:0.012508:0.007466:0.007466:0.003848:0.012604:0.011738:0.012334:0.003848:0.007466:0.012334:0.012508:0.010660:0.012508:0.011738:0.005330:0.006995:0.011738:0.003848:0.012950:0.011738:0.012508:0.005792:0.005330:0.006987:0.003848:0.011738:0.012334:0.018049:0.012508:0.006523:0.013143:0.007466:0.006523:0.013143:0.006523:0.003848:0.012450:0.005330
castration-resistant prostate carcinoma :@0.524242:0.871043:0.920476:0.871043:0.920476:0.855287:0.524242:0.855287:0.012450:0.013143:0.007466:0.006523:0.005792:0.013143:0.006523:0.003848:0.012604:0.011738:0.006388:0.005707:0.012508:0.007466:0.003848:0.007466:0.006523:0.013143:0.011738:0.006523:0.017838:0.013123:0.005715:0.012604:0.007466:0.006523:0.013143:0.006523:0.012508:0.017838:0.012450:0.013143:0.005659:0.012450:0.003848:0.011738:0.012604:0.018049:0.013143:0.005330
(mCRPC). Several small-molecule ligands :@0.524242:0.887341:0.920474:0.887341:0.920474:0.871585:0.524242:0.871585:0.007100:0.018049:0.015644:0.011680:0.011392:0.015644:0.007100:0.005330:0.008159:0.009583:0.012508:0.010660:0.012508:0.005792:0.013143:0.003848:0.008159:0.007466:0.018049:0.013143:0.003848:0.003848:0.006388:0.018049:0.012604:0.003848:0.012519:0.012450:0.011699:0.003848:0.012508:0.008159:0.003848:0.003848:0.012950:0.013143:0.011738:0.013181:0.007466:0.005330
have been developed, targeting PSMA. :@0.524242:0.903639:0.920495:0.903639:0.920495:0.887883:0.524242:0.887883:0.011738:0.013143:0.010660:0.012508:0.009833:0.013123:0.012508:0.012508:0.011738:0.009833:0.013181:0.012508:0.010660:0.012508:0.003848:0.012604:0.013123:0.012508:0.013181:0.005330:0.009833:0.006523:0.013143:0.005805:0.012950:0.012508:0.006523:0.003848:0.011738:0.012950:0.009833:0.011392:0.009583:0.017684:0.014239:0.005330:0.005330
Ga-68 PSMA is a diagnostic radionuclide :@0.524242:0.919938:0.920474:0.919938:0.920474:0.904182:0.524242:0.904182:0.016779:0.013143:0.006388:0.010660:0.010660:0.008074:0.011392:0.009583:0.017684:0.014239:0.008063:0.003848:0.007466:0.008063:0.013143:0.008063:0.013181:0.003848:0.013143:0.012950:0.011738:0.012604:0.007466:0.006523:0.003848:0.012450:0.008063:0.005792:0.013143:0.013181:0.003848:0.012604:0.011738:0.011699:0.012450:0.003848:0.003848:0.013181:0.012508:0.005330
available  for  PET imaging. PSMA  can be :@0.524242:0.936236:0.920499:0.936236:0.920499:0.920480:0.524242:0.920480:0.013143:0.010660:0.013143:0.003848:0.003848:0.013143:0.013123:0.003848:0.012508:0.005330:0.003290:0.006042:0.012604:0.005792:0.005330:0.003260:0.011392:0.010314:0.008197:0.008601:0.003848:0.018049:0.013143:0.012950:0.003848:0.011738:0.012950:0.005330:0.008601:0.011392:0.009583:0.017684:0.014239:0.005330:0.003262:0.012450:0.013143:0.011738:0.008601:0.013123:0.012508:0.005330